Compare Illumina, Inc. (ILMN) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Gartner Inc — how do they compare? Illumina, Inc. trades at $266.99 (market cap $39.95B), while Gartner Inc trades at $195.41 (market cap $12.34B). The key difference: Illumina, Inc. is far larger — about 3.2× Gartner Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Gartner Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Gartner Inc for 64 Days on average.
| ILMN | IT | |
|---|---|---|
Market Cap | $39.95B | $12.34B |
Volume | 3,169,503 | 919,809 |
Sector | Health | Technology |
52-Week High | $293.69 | $258.17 |
52-Week Low | $91.00 | $125.68 |
Typical Hold Time | 83 Days | 64 Days |
Enterprise Value | $41.31B | $14.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
Gartner (IT) trades at $185.77, up 0.46% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a 69.63% gross margin and 12% net income margin, though 2025 net income declined to $729 million. Recent news highlights AI advisory demand and a shareholder investigation, while analyst consensus is mixed with a $174.63 price target below the current price.
Outlook remains supported by high ROE and consulting industry growth, but risks include the shareholder fiduciary probe and volatile cash flows. The stock faces resistance near $188, with valuation metrics like P/E of 17.57 appearing reasonable if earnings stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
